Uveitis is an inflammation of the uvea, the pigmented layer between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins, which lead to swelling, redness, heat, and destroys tissues as specific white blood cells rush to the affected part.
&nbsp;
Symptoms of acute forms of Uveitis include ocular pain, photophobia, lacrimation, and redness. Uveitis is most often idiopathic but has been associated with traumatic, inflammatory, and infectious processes.
&nbsp;
Uveitis Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Uveitis in 7MM from 2019 to 2032 is segmented as:-&nbsp;
<ul>
<li>Total Prevalent Cases of Uveitis</li>
<li>Gender-Specific Diagnosed Prevalent Cases of Uveitis</li>
<li>Age-Specific Diagnosed Prevalent Cases of Uveitis</li>
<li>Type-Specific Diagnosed Prevalent Cases of Uveitis</li>
<li>Diagnosed Prevalence of Noninfectious Uveitis (NIU) by Anatomical Location</li>
<li>Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU)</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/uveitis-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Uveitis Epidemiology</a>&nbsp;
<ul>
<li>The total prevalent cases of Uveitis in the 7MM were ~1 Million in the year 2022&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>~115K madular edema cases were associated with Uveitis pateints in the United States</li>
</ul>
&nbsp;
<a style="color: #0047b2; background-color: transparent;" href="https://www.delveinsight.com/report-store/uveitis-market" target="_blank" rel="noopener noreferrer">Uveitis Market</a>
The therapeutic market of Uveitis in 7MM in 2022 was USD ~1.5 Billion&nbsp;&nbsp;
&nbsp;
Uveitis Market Drivers
<ul>
<li>Availability of ocular inserts</li>
<li>Orphan drug Status</li>
<li>Introduction of biologic drugs</li>
<li>Rich emerging pipeline with diverse ROA and MOA</li>
</ul>
&nbsp;
Uveitis Market Barriers
<ul>
<li>Effective therapies for chronic or recurrent Uveitis</li>
<li>Yet to be fully explored</li>
<li>Lack of treatment options which can restore normal vision</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/uveitis-pipeline-insight" target="_blank" rel="noopener noreferrer">Uveitis Emerging Drugs</a>
The emerging drugs of the Uveitis market are&nbsp;
<ul>
<li>ADX-102</li>
<li>Sirolimus</li>
<li>EGP-437</li>
<li>Suprachoroidal CLS-TA</li>
<li>Sarilumab</li>
<li>LME636 (OCS-02)</li>
<li>LFG316</li>
<li>Abatacept (Orenica)</li>
<li>EYS606</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Uveitis Key Players
The key players in the Uveitis market are
<ul>
<li>Aldeyra Therapeutics Inc</li>
<li>Santen</li>
<li>EyeGate Pharmaceuticals</li>
<li>Clearside Biomedical, Inc</li>
<li>Sanofi Aventis</li>
<li>Oculis Pharma</li>
<li>Novartis</li>
<li>Bristol-Myers Squibb Company</li>
<li>Eyevensys</li>
</ul>
And many others.&nbsp;
&nbsp;
Stay tuned for latest updates on <a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/blog/uveitis-market" target="_blank" rel="noopener noreferrer">Uveitis Market Landscape</a>

Uveitis Market

Uveitis Infographic

Uveitis Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.